key: cord-0963543-oedh30o0
authors: Moschetta, Laura; Fasolino, Giuseppe; Kuijpers, Robert W
title: Non-arteritic anterior ischaemic optic neuropathy sequential to SARS-CoV-2 virus pneumonia: preventable by endothelial protection?
date: 2021-07-19
journal: BMJ Case Rep
DOI: 10.1136/bcr-2020-240542
sha: ec00fa21e9a202f535b0c49aa6e88f4d89d82cd7
doc_id: 963543
cord_uid: oedh30o0

We present a case of non-arteritic anterior ischaemic optic neuropathy (NAION) with no ocular or systemic risk factors in a patient who recovered from a recent SARS-CoV-2 pneumonia. NAION is the most common acute optic neuropathy among individuals over 50 years of age. It results from a transient hypoperfusion of the optic nerve head circulation, especially in patients with low vascular compliance due to ocular or systemic risk factors. We attribute the ophthalmological condition to a SARS-CoV-2 virus-associated endotheliopathy that can be prevented with timely protection of endothelial function with vitamins D and K(2).

Non-arteritic anterior ischaemic optic neuropathy sequential to SARS-CoV-2 virus pneumonia: preventable by endothelial protection? SUMMARY We present a case of non-arteritic anterior ischaemic optic neuropathy (NAION) with no ocular or systemic risk factors in a patient who recovered from a recent SARS-CoV-2 pneumonia. NAION is the most common acute optic neuropathy among individuals over 50 years of age. It results from a transient hypoperfusion of the optic nerve head circulation, especially in patients with low vascular compliance due to ocular or systemic risk factors. We attribute the ophthalmological condition to a SARS-CoV-2 virus-associated endotheliopathy that can be prevented with timely protection of endothelial function with vitamins D and K 2 .

Late complications, mostly cerebral and cardiac, after COVID-19 pneumonia are reported in increasing numbers. These have been linked with hypercoagulability and associated lupus anticoagulant antibodies. However, endothelial dysfunction has also been implied. Non-arteritic anterior ischaemic optic neuropathy (NAION) has not been reported as a sequela of COVID-19 so far.

A 64-year-old Caucasian man presented at the emergency eye clinic with a 4-day history of right eye visual field reduction. Four weeks earlier, he had been discharged after 5-day hospitalisation for COVID-19 pneumonia. In summary, the patient was admitted to hospital because of dyspnoea 1 week after first symptoms of COVID-19. CT of the thorax showed typical ground-glass opacities with a score 15 of 25, compatible with COVID-19 pneumonia. PCR was positive for SARS-CoV-2.

For 4 days he was treated with high-flow nasal cannula oxygen without the need for mechanical ventilation or intubation. He was further treated with hydroxychloroquine (2×400 mg a day for 6 days) and acetaminophen (4×1 g a day for 5 days). Oxygen saturation was always above 90%. Blood pressure during hospitalisation ranged from 123/64 mm Hg to 136/82 mm Hg. No other therapy was given. The patient used no medication, is a nonsmoker, had no previous ophthalmological disease, no diabetes, no obesity, no hypercholesterolaemia nor other systemic diseases. No ocular or systemic risk factors for NAION were present.

Ophthalmological findings showed a relative afferent pupillary defect in the right eye, relative 

Embolism of short posterior ciliary arteries of optic nerve head is a rare cause of NAION. 1 Embolic occlusion of these arteries is seen on fluorescein fundus angiography as hypoperfusion choroidal area. Fluorescein fundus angiography did not show signs of short posterior ciliary artery embolism (figure 3).

A hypercoagulable state due to antiphospholipid antibodies 2 was ruled out. Also, anticardiolipin and lupus anticoagulant were negative, D-dimer had normalised and Von Willebrand factor antigen was normal (table 1) .

Arteritic anterior ischaemic optic neuropathy (AION) is a mandatory differential diagnosis to rule out in patient presenting with an ischaemic optic neuropathy. 1 The primary cause of AION is giant cell arteritis (GCA). 1 Figure 1 Fundus examination of right eye shows a pale optic nerve disc with sectorial swelling, dilated capillaries in the disc surface and some intrapapillary haemorrhages. The macula appears within normal limits with no signs of cilioretinal artery occlusion.

The differential diagnosis between NAION and GCA of posterior ciliary arteries is based on systemic and clinical features.

The patient had no clinical signs of GCA, that is, no jaw claudication, no headache, no scalp tenderness or other features.

Erythrocyte sedimentation rate increased in GCA was completely normal the day of the patient's presentation at the eye clinic (10 mm/hour) and in 2-month follow-up time (4 mm/ hour). At presentation, C reactive protein (CRP) was within normal range (12.7 mg/L) and significantly decreased compared with hospitalisation value (170.2 mg/L). At 2-month follow-up, Valsartan was started with intake in the morning to avoid nocturnal hypotension (80 mg per day) together with aspirin (80 mg per day) as secondary cardiovascular protection. Figure 4 Pseudo-thickening of the nerve fibre layer of the right eye due to papillary oedema. The abnormal thickening reduced in 2-month follow-up examination. RNFL, retinal nerve fibre layer.

At 2-month follow-up, superior swelling was reduced but inferior part was also involved. This aspect is highly suggestive of papillary oedema in progressive non-arteritic anterior ischaemic optic neuropathy. The macula appears within normal limits with no signs of cilioretinal artery occlusion.

Case report DISCUSSION We attribute the ophthalmological condition in our case to SARS-CoV-2 virus-associated endotheliopathy.

Emerging studies over SARS-CoV-2 virus and COVID-19 disease suggest that endotheliopathy is a central feature of its pathophysiology and leads to severe vascular systemic sequelae by loss of vascular compliance 2 including at the level of optic nerve. 3 Savastano et al 3 have recently reported the impact of SARS-CoV-2 infection on the microvascular network of optic nerve head in patients who recovered from COVID-19, 4 weeks after discharge. It results in an impairment in the blood supply to the peripapillary retinal nerve fibre layer characterised by a reduction of radial peripapillary capillary plexus density that has been previously correlated to visual field loss in NAION. 2 Furthermore, a recent study over lung perfusion abnormalities in patients with COVID-19 proposed possible underlying mechanisms, not only microthrombosis but also perfusion defects caused by vasoconstriction that brings to subsequential SARS-CoV-2-induced vasoplegia. 4 The transient hypoperfusion of optic nerve head circulation is indeed the most common cause of NAION. 1 No treatment is available to restore visual function in NAION. 1 Therefore, prevention is paramount. Endothelial function and integrity can be improved by vitamins D and K 2 . [5] [6] [7] [8] [9] Moreover, there is support that vitamin D deficiency is particularly common in patients with COVID-19 developing endothelial dysfunction sequels elsewhere. 5 6 Vitamin K 2 status may also be reduced in patients with COVID-19 and related to poor prognosis. 7 8 No test is available to measure vitamin K 2 status, but vitamin D level in our patient was markedly reduced (11.4 µg/L).

Based on the growing understanding of SAR-CoV-2 endotheliopathy, we propose considering endothelial reserve in patients with COVID-19 and initiating prophylactic protection to prevent ophthalmic and other systemic sequelae at the earliest moment of diagnosis. After the consultation of 4 June 2020, two medicines were prescribed: Valsartan and Aspirin. I have also been following a vitamin D cure since 4 June 2020. The diminished vision in the right eye has stabilized. The left eye is functioning normally. At the consultation on 2 July it was established that vision in the right was slightly improved. However, I was not aware of that improvement.

► Endotheliopathy is a central feature of COVID-19 disease. ► SARS-CoV-2 virus can impact the vascular compliance of the optic nerve head with a reduction of radial peripapillary capillary plexus density that can result in non-arteritic anterior ischaemic optic neuropathy. ► Endothelial protection by vitamins D and K 2 should be considered in all patients with COVID-19. ► Intervention studies are needed to assess the effect of the administration of vitamins D and K 2 on reducing the severity and complications of COVID-19 pneumonia.

Management of ischemic optic neuropathies

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study

Peripapillary retinal vascular involvement in early Post-COVID-19 patients

COVID-19: what iodine maps from perfusion CT can reveal-A prospective cohort study

Vitamin D and SARS-CoV-2 virus/ COVID-19 disease

Vitamin D and endothelial function

Reduced vitamin K status as a potentially modifiable risk factor of severe COVID-19

Vitamin D3 and K2 and their potential contribution to reducing the COVID-19 mortality rate

Vitamin K2 ameliorates damage of blood vessels by glucocorticoid: a potential mechanism for its protective effects in glucocorticoidinduced osteonecrosis of the femoral head in a rat model

Contributors LM made substantial contribution examining the patient and drafting the article. GF contributed to writing the article. RWK made the conceptual input for the article, scientific interpretation and writing the manuscript.

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Robert W Kuijpers http:// orcid. org/ 0000-0002-2026-9950Copyright 2021 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit https://www.bmj.com/company/products-services/rights-and-licensing/permissions/ BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.Become a Fellow of BMJ Case Reports today and you can: ► Submit as many cases as you like ► Enjoy fast sympathetic peer review and rapid publication of accepted articles ► Access all the published articles ► Re-use any of the published material for personal use and teaching without further permission

If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.Visit casereports.bmj.com for more articles like this and to become a Fellow